Author: paroukatos

20 Aug

Posted at 10:07h in Μεταβολικό Σύνδρομο by

Spyridon Koulouris, MD, PhD, Phivos Symeonides, MD, Konstantinos Triantafyllou, MD, Georgios Ioannidis, MD, Ilias Karabinos, MD, Theofanis Katostaras, PhD, Mahmud El-Ali, MD, Theodoros Theodoridis, MD, Ekaterini Vratsista, MD, Nikolaos Thalassinos, MD, Vassiliki Kokkinou, MD, Ioannis Nanas, MD, PhD, Stamatios Stamatelopoulos, MD, PhD, and Pavlos Toutouzas,...

20 Aug

Posted at 10:06h in Μεταβολικό Σύνδρομο by

Michael Schupp, BPharm; Jürgen Janke, PhD; Ronald Clasen, BPharm; Thomas Unger, MD; Ulrich Kintscher, MD Background: Αngiotensin type 1 receptor (AT1R) blockers (ARB) have been shown to reduce the incidence of type 2 diabetes mellitus by an unknown molecular mechanism. The peroxisome proliferator-activated receptor-_ (PPAR_) is the...

20 Aug

Posted at 09:51h in Μεταβολικό Σύνδρομο by

Introduction Evidence from a range of excellent clinical trials proves that lowering BP with several classes of antihypertensive drugs, including angiotensin II type 1 receptor blockers (ARBs), will reduce the complications of hypertension. ARBs, along with other antihypertensives, are beneficial in reducing stroke, coronary vascular disease...

20 Aug

Posted at 09:50h in Μεταβολικό Σύνδρομο by

Taro E. Akiyama, PhD,* Peter T. Meinke, PhD, and Joel P. Berger, PhD Metabolic syndrome (MS), a condition characterized by multiple related clinical disorders including insulin resistance, central obesity, hyperlipidemia, hypertension, and heart disease, is an increasingly prevalent disease in industrialized societies. The intense research interest...

20 Aug

Posted at 09:49h in Μεταβολικό Σύνδρομο by

Alexander Tenenbaum*1,2, Enrique Z Fisman1,2 and Michael Motro1,2 Abstract The metabolic syndrome is a highly prevalent clinical entity. The recent Adult Treatment Panel (ATP III) guidelines have called specific attention to the importance of targeting the cardiovascular risk factors of the metabolic syndrome as a method of...

20 Aug

Posted at 09:48h in Μεταβολικό Σύνδρομο by

Yau-Sheng Tsai,1 Hyo-Jeong Kim,2 Nobuyuki Takahashi,1 Hyung-Suk Kim,1 John R. Hagaman,1 Jason K. Kim,2 and Nobuyo Maeda1 1Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA. 2Department of Internal Medicine, Section of Endocrinology and Metabolism, Yale University School of Medicine, New...

20 Aug

Posted at 09:46h in Όργανα Στόχοι by

Hazel A. Bradleya, Charles Shey Wiysongeb, Jimmy A. Volminkc, Bongani M. Mayosib and Lionel H. Opied  Objective To quantify the effect of first-line antihypertensive treatment with beta-blockers on mortality, morbidity and withdrawal rates, compared with the other main classes of antihypertensive agents. Methods We identified eligible trials by searching...

20 Aug

Posted at 09:45h in Όργανα Στόχοι by

Anthony H. Barnett, M.D., Stephen C. Bain, M.D., Paul Bouter, Ph.D., Bengt Karlberg, M.D., Sten Madsbad, M.D., Jak Jervell, Ph.D.,  and Jukka Mustonen, Ph.D., for the Diabetics Exposed to Telmisartan and Enalapril Study Group* background: Few studies have directly compared the renoprotective effects of angiotensin II-receptor...

20 Aug

Posted at 09:40h in Στεφ. Νόσος-Καρδιακή Ανεπάρκεια by

George C. Sutton a, Jan Erik Otterstad b, Bridget-Anne Kirwan c, Zoltán Vokó d, Sophie de Brouwer c, Jacobus Lubsen c,e, Philip A. Poole-Wilson a,⁎ On behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators Cardiac Medicine, National Heart and Lung Institute, Imperial College...